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 Introduction 
 Multiple myeloma (MM) is a malignant B-cell neoplasm 
characterized by the accumulation of malignant plasma cells 
in the bone marrow. It is the second most common hema-
tological disorder [1], accounting for 2% of cancer deaths 
[2], with median survival times of 4 – 7 years [3]. Recently, an 
increasing number of people are being diagnosed with MM. 
It has a yearly incidence number of nearly 14 – 15 thousand 
that accounts for approximately 10% of all hematologic 
cancers in the United States [4,5]. 
 Th e treatment strategy for MM is an important step for 
patients since MM is currently still accepted as an incurable 
disease [6,7]. Bortezomib (Velcade  ®  ) is known to be eff ective 
in more than 200 types of cancer cell lines [8], and is the fi rst 
of a new class of anticancer agents known as proteasome 
inhibitors [8]. It is a dipeptide boronic acid derivative, and 
triggers apoptosis in MM by binding the catalytic site of 
the 26S proteasome with high affi  nity and specifi city with 
the boron atom in its structure [9 – 14]. Th e 26S proteasome 
appears to play an essential role in the targeted degradation 
of intracellular proteins that are responsible for regulating 
essential cellular functions, such as cell-cycle control, signal 
transduction, cellular adhesion, proliferation, development, 
survival and apoptosis [15,16]. Nuclear factor- κ B (NF- κ B) is 
a transcription factor that has a central role in bortezomib-
induced apoptosis, since it regulates genes involved in apop-
tosis and cell-cycle control [17]. Up to 80% of patients with 
MM have specifi c mutations in certain genes which regulate 
the NF- κ B pathway [18,19]. In MM, tumor cells and bone 
marrow stromal cells (BMSCs) indicate enhanced NF- κ B 
activity as compared to healthy cells [20 – 22]. Proteasome-
mediated activation of NF- κ B brings about the expression 
of multiple enzymes and cell cycle regulators, cytokines, 
cell adhesion molecules and anti-apoptotic factors inducing 
cell growth and survival [11,12,23]. Th erefore, it is important 
to both understand what is happening at the protein level 
underlying the NF- κ B pathway and solve the roles of dif-
ferentially expressed proteins. Although many studies from 
several research groups have been conducted regarding the 
molecular pathways of MM, studies of changes in protein 
profi les in response to bortezomib in MM cells have not been 
reported, to the best of our knowledge. 
 In this study, our results demonstrated that bortezomib 
has anti-proliferative and anti-apoptotic eff ects on U-266 
MM cells. More importantly, proteins involved in the NF- κ B 
pathway were determined by matrix-assisted laser desorp-
tion/ionization tandem time-of-fl ight (MALDI-TOF-TOF) 
mass spectrometry for the fi rst time. According to the mass 
spectrometric analysis, 20 protein spots were diff erentially 
expressed. Six proteins are related to cell signaling (spots 7, 
11, 14, 15, 23, 29), one protein has a role in survival (spot 34), 
one is a cell-cycle regulator (spot 4), two proteins are involved 
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in apoptosis (spots 2, 27), one protein is a tumor suppressor 
(spot 8), fi ve proteins take a key role in the immune defense 
mechanism (spots 9, 12, 18, 25, 35), one protein is involved 
in protein modifi cation and ubiquitination (spot 22) and 
three have other functions (spots 5, 6, 10). Among them, 
fi ve proteins were newly formed, four proteins were lost, 
four proteins were up-regulated and seven proteins were 
down-regulated in response to bortezomib as compared to 
untreated control cells. 
 Materials and methods 
 Cell culture 
 U-266 human MM cells were kindly obtained from the 
German Collection of Microorganisms and Cell Cultures 
(Germany). Th e cells were grown and maintained in RPMI-
1640 (Gibco Industries Inc., Los Angeles, USA) growth 
medium supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin – streptomycin (Invitrogen, USA) at 37 ° C 
under a humidifi ed atmosphere of 95% air and 5% CO 2 . Th e 
medium was refreshed every 3 days. 
 Cell proliferation assay 
 Bortezomib was obtained from LCLabs (USA). Th e stock 
solution of bortezomib was prepared in dimethyl sulfoxide 
(DMSO) at a concentration of 2.6 mmol/mL, stored in ali-
quots at    20 ° C and diluted in cell culture medium. 
 Anti-proliferative eff ects of bortezomib on U-266 MM 
cells were determined by XTT [2,3-bis-(2-methoxy-4-nitro-
5-sulfophenyl)-2 H -tetrazolium-5-carboxanilide] cell pro-
liferation assay. U-266 cells (2    10 4 /200  μ L) were seeded 
into 96-well plates containing 200  μ L growth medium in the 
absence and presence of increasing concentrations of bort-
ezomib. After a 72 h incubation period, 50  μ L XTT reagent 
was added to each well. Plates were then incubated for 4 h 
at 37 ° C in 5% CO 2 , and growth medium and XTT reagent 
were removed. Th e absorbances of the samples were mea-
sured under 492 nm wavelength of light by enzyme-linked 
immunosorbent assay (ELISA) reader (Multiskan Spectrum; 
Th ermo Electron Corporation, Finland) and the IC 50 value 
(concentration of drug that inhibits 50% of cell proliferation 
as compared to untreated control) of bortezomib was calcu-
lated from cell proliferation plots. 
 Caspase-3 activity 
 Changes in caspase-3 enzyme activity of U-266 MM cells in 
response to bortezomib were evaluated using a caspase-3 
colorimetric assay kit (R & D Systems, USA) as described 
previously [24]. In short, 1    10 6 cells were seeded in a six-
well plate in 2 mL growth medium in the absence or pres-
ence of increasing concentrations of bortezomib at 37 ° C 
in 5% CO 2 for 72 h. Untreated cells were used as the con-
trol group. After incubation, the cells were centrifuged at 
1000 rpm for 10 min and the cell pellet was lysed by adding 
50  μ L of chilled Cell Lysis Buff er (1  ). Th en, the cell lysate 
was incubated on ice for 10 min before centrifugation at 
14 000 rpm for 1 min. Th e supernatants were used to mea-
sure caspase-3 enzyme activity, and the reaction mixture 
was prepared in 96-well plates with the addition of 50  μ L 
of Reaction Buff er (2  , containing 10 mM dithiothreitol 
[DTT]), 50  μ L of sample and 5  μ L of caspase-3 colorimet-
ric substrate (DEVD-pNA) and incubated for 2 h at 37 ° C 
in 5% CO 2 . Th e absorbance of the reaction mixture was 
measured under 405 nm wavelength by ELISA reader (Mul-
tiskan Spectrum; Th ermo Electron Corporation). Caspase-3 
activity levels were normalized to protein concentrations 
determined by the Bradford protein assay [25]. 
 Loss of mitochondrial membrane potential 
 Th e loss of mitochondrial membrane potential (MMP) in 
U-266 MM cells in response to bortezomib was assessed 
by an APO LOGIX JC-1 MMP Detection Kit (Cell Technol-
ogy, USA). Briefl y, 1    10 6 cells were seeded in a six-well 
plate in 2 mL growth medium in the absence or presence 
of increasing concentrations of bortezomib at 37 ° C in 5% 
CO 2 for 72 h. Untreated cells were used as the control group. 
After this period, all samples were washed with 1    phos-
phate buff ered saline (PBS) before centrifugation at 1000 
rpm for 10 min. Supernatants were carefully removed from 
the pellets and discarded. Th en the pellets were dissolved 
in 500  μ L of JC-1 dye (1%) and the cells were incubated at 
37 ° C in 5% CO 2 for 30 min. Next, the mixtures were cen-
trifuged at 1000 rpm for 5 min and supernatants were 
carefully removed again. Subsequently, 2 mL of 1    Assay 
Buff er was added to the pellets and vortexed for homogeni-
zation. Th e centrifugation step was repeated with the same 
conditions to remove the excess dye. All the pellets were 
resuspended with 500  μ L 1    Assay Buff er and 150  μ L from 
each of them was seeded into black 96-well plates. While 
the aggregate red form of the dye has absorption/emission 
maxima of 585/590 nm, the monomeric green form of the 
dye released to the cytoplasm because of the loss of MMP 
has absorption/emission maxima of 510/527 nm. Th e plate 
was read using these wavelengths by fl uorescence ELISA 
reader. Finally, green/red (510/585) values were calculated 
to determine the changes in MMP. 
 Total protein extraction 
 In order to extract the total proteins from untreated and 
bortezomib treated U-266 cells, whole cell suspension was 
centrifuged at 1000 rpm for 10 min at room temperature. 
After centrifugation, the supernatant was removed and the 
pellet was resuspended in 50  μ L of chilled Cell Lysis Buff er 
(containing sodium chloride, potassium chloride, sodium 
phosphate dibasic, potassium phosphate monobasic, Triton 
X100 and water) and incubated on ice for 10 min. Following 
the addition of Cell Lysis Buff er, samples were centrifuged 
at 14 000 rpm for 1 min at 4 ° C. Th e supernatant, which was 
the total protein of our samples, was transferred to a fresh 
tube and used for further studies (two-dimensional [2D]-
polyacrylamide gel electrophoresis [PAGE]). Protein concen-
trations of the samples were determined using the Bradford 
protein assay as described previously [25]. 
 Two-dimensional PAGE 
 All 2D-PAGE equipment and immobilized pH gradient 
(IPG) strips (3 – 10 NL, 17 cm) were obtained from Bio-Rad 
(USA). Chemicals used in 2D-PAGE experiments were 
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purchased from Sigma, AppliChem and Amersham 
Biosciences (Piscataway, USA). 
 Isoelectric focusing 
 Passive rehydration was performed for the rehydration of 
strips. Th e procedure was carried out in accordance with the 
user ’ s manual for the IPG system. Protein samples were recon-
stituted with rehydration buff er which contained urea (4.8 g, 
8 M), CHAPS (3-[(3-cholamidopropyl)-dimethylammonio]-
1-propane sulfonate) (0.2 g, 2%), DTT (0.077 g, 50 mM), 
ampholytes (pH 3 – 10) (100  μ L, 0.2%) and Bromophenol Blue 
(1 – 2  μ L, 0.5%). Th e reorganized protein applied to the strips 
for bortezomib treated U-266 cells was 408  μ g, and 414.4  μ g 
protein for untreated U-266 cells as control. 
 Isoelectric focusing (IEF) was performed at room tem-
perature and 50  μ A in three steps with both diff erent volt-
ages and times. In the fi rst step, 500 V was applied for 1 h, 
1000 V was applied for 1 h in the second step, and 8000 V 
was applied for 8 h as a fi nal step. 
 Sodium dodecyl sulfate 
 Prior to sodium dodecyl sulfate (SDS)-PAGE, focused IPG 
strips were equilibrated in Equilibration Buff ers (I and II). 
Equilibration Buff er I contains DTT (0.4 g/20 mL), Tris-HCl 
pH 8.8 (5 mL, 1.5 M), glycerol (4 mL), urea (7.2 g/20 mL), 
SDS (0.4 g/20 mL) and ultrapure H 2 O (5 mL). Equilibration 
Buff er II contains iodoacetamide (0.5 g/20 mL) instead of 
DTT. Strips were loaded onto a 12% SDS-polyacrylamide 
gel. In order to control electrophoresis cooling, water cir-
culation was used, and electrophoresis was started at a 
constant current of 32 mA for 30 min, followed by 50 mA 
for 5 – 6 h. To monitor the progress of electrophoresis, 
Bromophenol Blue was used. 
 Gel staining and image analysis 
 After electrophoresis, a MALDI-TOF mass spectrometry-
compatible silver staining method was performed, as 
described previously [26]. 
 After the staining process, gels were scanned, and photo-
graphed by an Olympus DP25 digital camera system. Th en 
image analysis, spot matching and determination of diff er-
ent protein spots were performed using DECODON Delta2D 
Version 4.3 software, and the diff erentiated proteins were 
determined and cut from the gel to be identifi ed by mass 
spectrometry. 
 In-gel digestion and peptide sequencing 
 Diff erentially expressed protein spots were in-gel digested 
overnight before mass spectrometry analysis, according to 
the procedure previously described by Shevchenko, with 
some modifi cations [27]. Sequencing grade modifi ed trypsin 
was from Promega Corporation (USA). 
 ZipTip  ®  pipette tips were obtained from Millipore Corpo-
ration (USA). Peptides were desalted and concentrated using 
C18 micro-columns (Eppendorf PerfectPure; Millipore) 
according to the manufacturer ’ s protocol. 
 Protein identifi cation by mass spectrometry 
 After the in-gel digestion procedure, peptides were eluted with 
50% acetonitrile and 0.1% trifl uoroacetic acid (TFA) and mixed 
1:1 with 10 mg/mL  α -cyano 4-hydroxy cinnamic acid (used as 
a matrix) in acetonitrile prior to spotting onto a stainless steel 
MALDI target plate. Th e peptide masses from two samples 
(bortezomib and control group) were analyzed by a MALDI-
TOF-TOF mass spectrometer (Bruker, Bremen, Germany). Th e 
sequence of the diff entially expressed protein spots was found 
using NCBInr (National Center for Biotechnology Informa-
tion, Bethesda, USA) and SwissProt protein databases. 
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 Figure 1. Antiproliferative eff ects of bortezomib on U-266 cells. Th e 
IC 50  concentration of bortezomib was determined by XTT assay. Th e 
XTT assays were performed using triplicate samples in at least two 
independent experiments. Th e error bars represent the standard 
deviations. 
 Figure 2. Percent changes in caspase-3 activity in response to 
bortezomib in U-266 cells. Th e results are the means of two independent 
experiments. Th e error bars represent the standard deviations. 
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 Figure 3. Percent changes in cytoplasmic/mitochondrial JC-1 in 
bortezomib treated U-266 cells. Th e results are the means of two 
independent experiments. Th e error bars represent the standard 
deviations. 
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 Comparison of protein profi les between untreated 
and bortezomib-treated U-266 cells 
 In order to identify changes in protein profiles, isolated 
proteins were analyzed by 2D-PAGE. Protein isolation 
and 2D-PAGE experiments were repeated four times. A 
mass spectrometry-compatible silver staining procedure 
was applied to increase the sensitivity [26]. The gel maps 
derived from untreated and bortezomib treated groups 
indicated a broad distribution of spots in a pI range from 
3.0 to 10.0 (Figure 4). 
 In order to elucidate and compare protein profi les of 
untreated and bortezomib-treated U-266 cells, two indi-
vidual gel images were imported into gel analysis software 
DECODON Delta2D Version 4.3. With the help of this soft-
ware, the 2D-PAGE gels were superposed and comparative 
detailed analysis was performed. According to the analysis, 
37 protein spots were diff erentially expressed. Among them, 
fi ve proteins were newly formed (Figure 5a), 10 proteins lost 
(Figure 5b), 12 proteins increased (Figure 5c) and 10 proteins 
decreased (Figure 5d) as compared to the control group 
(untreated cells) (Figure 5). Th ese spots were numbered 
from 1 to 37, colored and labeled: newly formed proteins 
were marked with green (Y), lost proteins were marked with 
red (K), increased proteins were marked with blue (M) and 
decreased proteins were marked with black (S). 
 Identifi cation and categorization of diff erentially 
expressed proteins in response to bortezomib 
 After labeling, black and red colored spots were cut from 
control group gels and others (green and blue) were cut from 
bortezomib treated group gels for enzymatic digestion using 
 Results 
 Bortezomib decreased proliferation of U-266 cells 
in a dose-dependent manner 
 U-266 cells were treated with increasing concentrations of 
bortezomib for 72 h, and the XTT cell proliferation assay 
was carried out in order to determine the anti-proliferative 
eff ects of bortezomib. Th ere were 3, 4, 15, 32, 57, 73 and 79% 
decreases in cell proliferation in response to 0.1, 1, 5, 10, 
20, 50 and 70 nM bortezomib, respectively, as compared to 
untreated cells (Figure 1). Th e IC 50 value of bortezomib was 
calculated from the cell proliferation plots and found to be 
17 nM (Figure 1). 
 Bortezomib induced apoptosis through loss of MMP 
and increased caspase-3 activity in U-266 cells 
 In order to evaluate the apoptotic eff ects of bortezomib on 
U-266 cells, U-266 cells were treated with three diff erent con-
centrations of bortezomib, and loss of mitochondrial mem-
brane potential and changes in caspase-3 enzyme activity 
were determined. As shown in Figure 2, caspase-3 activity 
was increased 1.06-, 1.13- and 1.17-fold in response to 1, 
10 and 20 nM bortezomib, respectively, as compared to the 
untreated control group. 
 In order to confi rm the caspase-3 activity results, the 
same set of experiments were done and changes in mito-
chondrial membrane potential were determined. Th e results 
revealed that there were 1.34-, 1.85- and 2.14-fold increases 
in loss of MMP in response to the same concentrations of 
bortezomib, respectively, as compared with untreated cells 
(Figure 3). 
 Figure 4. Representative overview of 2D PAGE maps of untreated and 17 nM bortezomib treated human U-266 cells. IEF as the fi rst dimension 
separation was over a pH range 3–10, while the second dimension separation was carried out by SDS-PAGE in a 12% polyacrylamide gel and gels 
were silver stained. Th e circles indicate the diff erentiated protein spots. 
  Protein profi les in response to bortezomib 1065
trypsin. Th en samples were analyzed by MALDI-TOF-TOF 
mass spectrometry and mass spectrometric data were com-
pared to the protein database for sequence matches. 
 In our experiments, protein spot determination was car-
ried out according to isoelectric point, molecular mass, 
sequence coverage and Mascot Mowse score. According to 
these parameters and mass spectrometric analysis, the most 
important 20 proteins related to the mechanism of the eff ect 
of the anticancer agent on the cells were listed. Table I shows 
these proteins, which have functions ranging from cell sig-
naling transduction, cell cycle regulation and apoptosis to 
immune defense mechanism in response to bortezomib. 
Figure 6 illustrates categorization of the biological functions 
of the diff erentially expressed proteins. 
 Discussion 
 Bortezomib is the fi rst of a new class of anticancer agents 
known as proteasome inhibitors. Although bortezomib 
is antiproliferative and apoptotic to more than 200 diff er-
ent cancer cell lines, signifi cant problems have arisen in 
response to bortezomib in patients with MM. Th us, it is of 
vital importance to determine the changes in total protein 
levels in response to bortezomib. In this study, we demon-
strated 37 diff erentially expressed protein spots (fi ve proteins 
newly formed, 10 proteins lost, 12 proteins up-regulated and 
10 proteins down-regulated) in bortezomib-treated MM cells 
as compared to untreated cells. 
 Th e lost proteins were signaling threshold-regulating 
transmembrane adapter 1, paxillin, caspase recruitment 
domain-containing protein 14 and NF- κ B inhibitor delta. Th e 
basic function of signaling threshold-regulating transmem-
brane adapter 1 is to regulate TCR (T-cell antigen receptor)-
mediated signaling negatively in T-cells [28].  Furthermore, 
it is specifi cally expressed in T- and B-cell lymphomas and 
present in plasma cells [29,30]. Paxillin is an important 
cytoskeletal protein with function in actin- membrane 
attachment at sites of cell adhesion to the extracellular 
 Figure 5. 2-D PAGE images of U-266 cells in response to bortezomib: (a) newly formed (rectangles), (b) lost (diamonds), (c) increased (circles) and 
(d) decreased protein spots (hexagons). All labeled spots were identifi ed by mass spectrometry and database search. 
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infl ammation, immunity, diff erentiation, cell growth, tum-
origenesis and apoptosis [34,35]. Th ese proteins were lost in 
response to bortezomib, and these fi ndings are in agreement 
with the literature. It has been shown that bortezomib treat-
ment induces apoptosis through the NF- κ B pathway [17]. 
 Th e newly formed proteins were apoptosis regula-
tory protein Siva, suppressor of tumorigenicity 7 protein, 
mitogen-activated protein kinase kinase kinase kinase 1, 
interleukin-32 and glutathione peroxidase 3. Apoptosis 
is a significant part of cell cycle regulation, especially in 
cancerous cells. Apoptosis regulatory protein Siva induces 
CD27-mediated apoptosis and also inhibits Bcl-2L1 
isoform Bcl-x(L) anti-apoptotic activity [36]. It is also 
inhibits activation of NF- κ B and promotes T-cell receptor-
mediated apoptosis [37]. Suppressor of tumorigenicity 
7 protein acts as a tumor suppressor [38]. It has been 
shown that mitogen-activated protein kinase kinase kinase 
kinase 1 acts upstream of the Jun N-terminal pathway 
[39,40]. It also plays a key role in hematopoietic lineage 
decisions and growth regulation. As well, it is expressed 
primarily in hematopoietic organs, especially bone marrow 
[41]. Interleukin-32 is a cytokine and is responsible for innate 
and adaptive immune responses [42]. Moreover, it induces 
matrix [31]. Caspase recruitment domain-containing protein 
14 activates NF- κ B via Bcl-10 and stimulates the phosphory-
lation of Bcl-10 [32]. NF- κ B inhibitor delta is responsible for 
regulating the expression of interleukins IL-2, IL-6 and other 
cytokines through regulation of NF- κ B activity, similarly 
to caspase recruitment domain-containing protein 14 [33]. 
NF- κ B is a transcription factor which is present in almost all 
cell types and is involved in many biological process such as 
30%
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 Figure 6. Categorization of biological functions of diff erentially 
expressed proteins. 
 Table I. Diff erentially expressed proteins and their functions. 
Spot name Protein name Function
Lost proteins Spot 14 SIT1  – signaling threshold-regulating 
transmembrane adapter 1
Cell signaling (regulation of TCR [T-cell antigen receptor]-mediated 
signaling)
Spot 15 CAR14  – caspase recruitment 
domain-containing protein 14
Cell signaling (activation of nuclear factor- κ B [NF- κ B] via Bcl-10)
Spot 23 IKBD  – NF- κ B inhibitor delta Cell signaling (regulation of NF- κ B activity)
Spot 5 PAXI  – (paxillin) Other function (involved in actin-membrane attachment at sites of 
cell adhesion to the extracellular matrix)
Newly formed 
proteins
Spot 27 Siva  – apoptosis regulatory protein Siva Apoptosis (inducing CD27-mediated apoptosis and inhibiting the 
activation of NF- κ B)
Spot 8 ST7  – suppressor of tumorigenicity 
7 protein
Tumor suppressor
Spot 7 Mitogen-activated protein kinase kinase 
kinase kinase 1
Cell signaling (upstream of the Jun N-terminal pathway) and growth 
regulation
Spot 35 IL-32  – interleukin-32 Immune defense mechanism (inducing various cytokines such as 
TNF- α and IL-8 and activating typical cytokine signal pathways of 
NF- κ B and p38 MAPK)
Spot 6 GPX3  – glutathione peroxidase 3 Other function (protection of cells and enzymes from oxidative 
damage)
Up-regulated 
proteins
Spot 2 CASP3  – caspase-3 Apoptosis (activation cascade of caspases responsible for apoptosis 
execution)
Spot 4 UBE2C  – ubiquitin-conjugating 
enzyme E2C
Cell cycle regulator (acting as essential factor of the anaphase 
promoting complex/cyclosome [APC/C], a cell cycle-regulated 
ubiquitin ligase that controls progression through mitosis)
Spot 34 RAB25  – Ras-related protein Rab-25 Cell survival (regulation of cell survival)
Spot 18 CLC5A  – C-type lectin domain family 
5 member A
Immune defense mechanism (positive regulator of 
osteoclastogenesis)
Down-regulated 
proteins
Spot 11 SOCS3  – suppressor of cytokine 
signaling 3
Cell signaling (part of a classical negative feedback system that 
regulates cytokine signal transduction)
Spot 29 PYDC1  – pyrin domain-containing 
protein 1
Cell signaling (suppresses kinase activity of NF- κ B inhibitor kinase 
[I κ K] complex, expression of NF- κ B inducible genes and inhibits 
NF- κ B activation by cytokines)
Spot 22 CHIP  – E3 ubiquitin-protein ligase CHIP Protein modifi cation and protein ubiquitination (targeting 
misfolded chaperone substrates toward proteasomal degradation)
Spot 9 BST2  – bone marrow stromal antigen 2 Immune defense mechanism (involved in pre-B-cell growth)
Spot 12 TN13B  – tumor necrosis factor ligand 
superfamily member 13B
Immune defense mechanism (promoting the survival of mature 
B-cells and the B-cell response)
Spot 25 TNR17  – tumor necrosis factor receptor 
superfamily member 17
Immune defense mechanism (promoting B-cell survival and playing 
a role in the regulation of humoral immunity and activating NF- κ B 
and JNK)
Spot 10 MKNK1  – MAP kinase-interacting 
serine/threonine-protein kinase 1
Other function (response to environmental stress and cytokines)
 TNF- α , tumor necrosis factor- α ; IL-8, interleukin-8; MAPK, mitogen-activated protein kinase. 
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other hand, severe side eff ects of bortezomib may also 
be explained by the changes in levels of these proteins. 
Th e changes in total proteins of U-266 cells in response to 
bortezomib were determined by MALDI-TOF-TOF mass 
spectrometry for the fi rst time. 
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